You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Filgotinib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Filgotinib?

Filgotinib is an investigational drug.

There have been 35 clinical trials for Filgotinib. The most recent clinical trial was a Phase 3 trial, which was initiated on May 12th 2021.

The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Colitis, Ulcerative. The leading clinical trial sponsors are Galapagos NV, Gilead Sciences, and Leiden University Medical Center.

There are one hundred and thirty-four US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Filgotinib
TitleSponsorPhase
Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsGalapagos NVPhase 1
A Phase 3 Program Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisGalapagos NVPhase 3
Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisGalapagos NVPhase 4

See all Filgotinib clinical trials

Clinical Trial Summary for Filgotinib

Top disease conditions for Filgotinib
trials0246810121416ArthritisArthritis, RheumatoidColitis, UlcerativeSpondylitis[disabled in preview]
Top clinical trial sponsors for Filgotinib
trials051015202530Galapagos NVGilead SciencesLeiden University Medical Center[disabled in preview]

See all Filgotinib clinical trials

US Patents for Filgotinib

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Filgotinib ⤷  Subscribe Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA) ⤷  Subscribe
Filgotinib ⤷  Subscribe Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA) ⤷  Subscribe
Filgotinib ⤷  Subscribe Compounds CHIESI FARMACEUTICI S.P.A. (Parma, IT) ⤷  Subscribe
Filgotinib ⤷  Subscribe Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Subscribe
Filgotinib ⤷  Subscribe Kinase inhibitors Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) ⤷  Subscribe
Filgotinib ⤷  Subscribe Imidazopyridazine compounds Pfizer Inc. (New York, NY) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 6 of 6 entries

International Patents for Filgotinib

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Filgotinib Canada CA2920534 2033-08-12 ⤷  Subscribe
Filgotinib European Patent Office EP3033079 2033-08-12 ⤷  Subscribe
Filgotinib Japan JP2016528251 2033-08-12 ⤷  Subscribe
Filgotinib Japan JP2019031546 2033-08-12 ⤷  Subscribe
Filgotinib Japan JP2021008475 2033-08-12 ⤷  Subscribe
Filgotinib Spain ES2709509 2033-08-12 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 6 of 6 entries

Filgotinib: Development Update and Market Projections

Introduction

Filgotinib, developed by Galapagos and Gilead, is a Janus kinase (JAK) inhibitor that has been under scrutiny for its potential in treating various autoimmune diseases. Here, we will delve into the current development status and market projections for this drug candidate.

Regulatory Status and Development Milestones

European and Japanese Approvals

Filgotinib, marketed as Jyseleca, has received approvals from the European Commission and the Japanese Ministry of Health, Labour and Welfare for the treatment of moderate-to-severe active rheumatoid arthritis (RA)[2][3].

US Regulatory Challenges

Despite European and Japanese approvals, the drug has faced significant regulatory hurdles in the US. The FDA issued a Complete Response Letter (CRL) in August 2020, requiring additional data from ongoing Phase II trials (MANTA and MANTA-RAy) to address concerns over sperm parameters and the higher dose of the drug. As a result, Gilead has decided not to pursue FDA approval for RA in the US without conducting substantial additional clinical studies[2][3].

Current Development Focus

Inflammatory Bowel Disease (IBD)

Gilead and Galapagos continue to investigate filgotinib's potential in treating IBD. Gilead retains operational responsibility for trials in Crohn’s disease, while Galapagos is responsible for trials in ulcerative colitis (UC). Filgotinib is under review by the European Medicines Agency (EMA) for UC and is expected to be submitted to the Japanese Ministry of Health, Labour and Welfare in the near future[3].

Other Indications

Filgotinib is also in various stages of development for other autoimmune indications, including psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, uveitis, lupus nephritis, cutaneous lupus erythematosus, and Sjogren’s syndrome[2].

Market Projections

Global Rheumatoid Arthritis Market

The global RA market is substantial, with the 2019 market size estimated at $25.2 billion across eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Australia). The US accounts for a significant portion of this market, with $18.7 billion in sales. However, the delayed US approval of filgotinib has impacted its potential market share[2].

Sales Projections

Initially, industry forecasts suggested that filgotinib could achieve peak sales of $4-6 billion, assuming superior safety profiles. However, due to the FDA's concerns and the subsequent decision not to pursue US approval for RA, these projections have been revised downward. GlobalData now expects that while filgotinib may still reach blockbuster status, it is unlikely to achieve the initially anticipated high sales figures[2].

Competitive Landscape

The JAK inhibitor market is competitive, with other drugs like Pfizer’s Xeljanz (tofacitinib), Eli Lilly and Incyte’s Olumiant (baricitinib), and AbbVie’s Rinvoq (upadacitinib) already established. The market share is expected to be more evenly distributed among these competitors, given the safety concerns associated with filgotinib[2].

Financial Implications

Revenue Impact

The delayed US approval and the decision not to pursue it for RA have resulted in significant lost revenue. GlobalData estimates that the delay in US approval could result in nearly $800 million in lost revenue from the RA market[2].

Collaboration and Commercialization

Under the new commercialization agreement, Galapagos will assume sole responsibility for filgotinib in Europe, including all future indications. Galapagos will receive payments from Gilead and will be responsible for European commercialization, while Gilead will retain commercial rights outside of Europe and receive royalties from European sales[3].

Conclusion

Filgotinib, despite its promising clinical profile, faces significant challenges in the US market due to regulatory concerns. While it has secured approvals in Europe and Japan, the delayed and potentially absent US approval has dampened its market projections. However, Galapagos and Gilead continue to explore its potential in other autoimmune indications and regions.

Key Takeaways

  • Regulatory Challenges: Filgotinib has faced significant regulatory hurdles in the US, leading to a decision not to pursue FDA approval for RA.
  • European and Japanese Approvals: The drug has been approved for RA in Europe and Japan.
  • Market Projections: Revised downward due to US regulatory issues; still expected to reach blockbuster status but with lower sales figures.
  • Competitive Landscape: The JAK inhibitor market is highly competitive, with filgotinib facing competition from established drugs.
  • Financial Implications: Significant lost revenue due to delayed US approval.

FAQs

Q1: What is the current regulatory status of filgotinib in the US?

Filgotinib has not received FDA approval for rheumatoid arthritis in the US due to regulatory concerns, and Gilead has decided not to pursue it without additional clinical studies.

Q2: In which regions is filgotinib approved for rheumatoid arthritis?

Filgotinib is approved for RA in Europe and Japan.

Q3: What are the other indications being explored for filgotinib?

Filgotinib is being investigated for psoriatic arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, uveitis, lupus nephritis, cutaneous lupus erythematosus, and Sjogren’s syndrome.

Q4: How has the regulatory delay impacted the market projections for filgotinib?

The delay in US approval has significantly reduced the projected sales figures for filgotinib, although it is still expected to reach blockbuster status.

Q5: Who is responsible for the commercialization of filgotinib in Europe?

Galapagos is responsible for the commercialization of filgotinib in Europe, including all future indications.

Sources

  1. Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update - Galapagos[1].
  2. Forecast for Gilead and Galapagos' Jyseleca (filgotinib) in US looks guarded - Pharmaceutical Technology[2].
  3. Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib) - Gilead[3].
  4. Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire[4].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.